Does the American Diabetes Association work for patients or companies?
Critics argue that the American Diabetes Association has long downplayed the role of diet—especially carbohydrate restriction—in preventing and reversing type 2 diabetes, while promoting guidance and sponsored recipes that align with food and pharmaceutical industry interests. Commenters highlight emerging evidence that low‑carb or very low‑calorie diets can put type 2 diabetes into remission, and raise concerns about artificial sweeteners like Splenda, which some studies link to metabolic problems. The exchange reflects broader mistrust of health institutions, with many seeing misaligned financial incentives and weak nutrition advice as contributing to a costly, largely preventable public health crisis.
Perceived ADA Misalignment and Conflicts of Interest
- Many commenters see the ADA as captured by corporate funders and not strongly aligned with patients’ interests.
- Sponsorships (e.g., from artificial sweetener companies) and branded recipes on ADA platforms are cited as emblematic conflicts.
- Some express disappointment the lawsuit settled before discovery, hoping investigations might expose internal decision-making.
Dietary Guidance, Carbs, and Diabetes Management
- Several diabetics and family members criticize ADA dietary recommendations as too carb-heavy and “worse than useless.”
- Strong pro–low-carb voices argue carbs drive hyperglycemia and insulin resistance, claiming low-carb or ketogenic diets can reverse type 2 and greatly aid glycemic control.
- Others counter that “carbs themselves” are not inherently harmful; the issue is refined, nutrient-poor foods and overall excess calories.
- There is disagreement over whether very low-carb diets are broadly healthy or sustainable long term.
Type 1 vs Type 2 and “Reversal”
- Broad agreement that type 1 diabetes requires exogenous insulin; diet and exercise can improve control but not eliminate this.
- Some push back on absolute language (“always no insulin”), citing residual endogenous insulin and variability.
- Multiple commenters reference research and personal experience suggesting many with type 2 can achieve remission via substantial weight loss or low-carb / very-low-calorie protocols (e.g., Newcastle Protocol, ketogenic programs).
- Skeptics question sustainability of severe calorie restriction and highlight risks like muscle loss and later weight regain.
Prediabetes and Diagnostic Thresholds
- One thread challenges whether “prediabetes” is a meaningful disease vs a risk label, noting the cutoff is near population medians.
- Others respond that elevated HbA1c is strongly associated with higher future diabetes and mortality risk; thresholds are somewhat arbitrary but clinically useful.
- Debate centers on semantics (“disease” vs “risk factor”) rather than on whether metabolic health is widely poor.
Artificial Sweeteners and Splenda Sponsorship
- A major subthread critiques ADA’s close relationship with Splenda, including sponsored newsletter content and many Splenda-based recipes.
- Cited studies associate non-sugar sweeteners with impaired glucose tolerance, obesity, cardiovascular disease, and higher type 2 risk, though causal direction is contested.
- Some argue artificial sweeteners are still valuable sugar substitutes and self-monitoring shows no acute glycemic impact; others stress microbiome and hormonal effects and WHO’s cautionary guidance.
Institutions, Incentives, and Expertise
- Commenters generalize from ADA to a broader “principal–agent” problem: many associations, unions, and bureaucracies drift toward self-preservation over mission.
- This fuels skepticism of “trust the experts / don’t do your own research” messaging; several argue laypeople can and should critically evaluate evidence, while others warn most people lack the skills and should rely on scientific consensus.
- Economic incentives are highlighted: pharma profits from chronic management; insurers and society bear costs of complications, suggesting misaligned motivations around prevention and cure.